Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12


Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.

Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K.

Diabetes. 2013 Sep;62(9):3232-40. doi: 10.2337/db13-0430. Epub 2013 Jul 8.


Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zöllner SK, Pop-Busui R.

J Clin Psychopharmacol. 2012 Apr;32(2):261-5. doi: 10.1097/JCP.0b013e3182485888.


A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

Albaugh VL, Singareddy R, Mauger D, Lynch CJ.

PLoS One. 2011;6(8):e22662. doi: 10.1371/journal.pone.0022662. Epub 2011 Aug 9.


Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

Kim SH, Reaven G, Lindley S.

Int Clin Psychopharmacol. 2011 Jan;26(1):43-7. doi: 10.1097/YIC.0b013e3283400cd3.


Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Nielsen J, Skadhede S, Correll CU.

Neuropsychopharmacology. 2010 Aug;35(9):1997-2004. doi: 10.1038/npp.2010.78. Epub 2010 Jun 2.


Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents.

Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, Lindley S.

J Psychiatr Res. 2010 Jun;44(8):493-8. doi: 10.1016/j.jpsychires.2009.11.007. Epub 2009 Dec 3.


Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC.

J Psychiatr Pract. 2009 Jul;15(4):251-61. doi: 10.1097/01.pra.0000358312.99233.ef.


Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.


Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

Hum Psychopharmacol. 2009 Apr;24(3):225-32. doi: 10.1002/hup.1012.


A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC.

Acta Psychiatr Scand. 2009 Jun;119(6):457-65. doi: 10.1111/j.1600-0447.2008.01325.x. Epub 2009 Jan 12.


Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Apr;101(1-3):273-86. doi: 10.1016/j.schres.2007.12.487. Epub 2008 Feb 6.


A discrete Single Delay Model for the Intra-Venous Glucose Tolerance Test.

Panunzi S, Palumbo P, De Gaetano A.

Theor Biol Med Model. 2007 Sep 12;4:35.

Supplemental Content

Support Center